MedTrace Logo

Parametric PET of Genitourinary Cancer

NCT04020978 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2026-03-10

No results posted yet for this study

Summary

Metastatic kidney cancer is usually treated with targeted therapy or immunotherapy which is costly and has low response rate. The current standard care is to perform anatomical imaging studies after a few cycles (months) of treatment to evaluate response. This approach exposes many patients to highly toxic, high expensive treatment without any benefit for months and delays initiation of other effective therapies. The goal of this study is to evaluate a parametric PET method that potentially identify response and assess drug efficacy with a few days to weeks of treatment.

Conditions

  • Genitourinary Cancer

Interventions

DIAGNOSTIC_TEST

Parametric PET/CT

Each patient will undergo a dynamic F18-FDG PET/CT scan at baseline and 2-week post therapy.

Sponsors & Collaborators

  • University of California, Davis

    lead OTHER

Principal Investigators

  • Guobao Wang, PhD · University of California, Davis

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-16
Primary Completion
2023-01-05
Completion
2023-12-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04020978 on ClinicalTrials.gov